N° 87
Date finished: July 2018
Batch: WS13
Country of origin: Germany
Supervisor(s): Dr. Lenz (TUB), Prof. Hildebrandt (TUB)
Area PhD: Biochemistry and application of bidirectional, NAD+ reducing [NiFe]- hydrogenases
Present occupation:
11/2020 - now: Medical Science Liaison at UCB1,2, Berlin
Past occupations:
11/2018 - 11/2020: Account manager, Curium Pharma, Berlin
11/2017 - 09/2017: PostDoc in the group of Prof. Peter Neubauer (TU Berlin), Berlin
1 founded 1928, approx. 7.600 employees, revenue 6 Bio.€
2 UCB (Union Chimique Belge) is a multinational biopharmaceutical company headquartered in Brussels, which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system (CNS) disorders (including epilepsy), inflammatory disorders (including allergy), and oncology.